CN102641317A - Golden wave extract and application thereof in preparation of antidiabetic agent - Google Patents
Golden wave extract and application thereof in preparation of antidiabetic agent Download PDFInfo
- Publication number
- CN102641317A CN102641317A CN2012101418311A CN201210141831A CN102641317A CN 102641317 A CN102641317 A CN 102641317A CN 2012101418311 A CN2012101418311 A CN 2012101418311A CN 201210141831 A CN201210141831 A CN 201210141831A CN 102641317 A CN102641317 A CN 102641317A
- Authority
- CN
- China
- Prior art keywords
- extract
- coreopsis basalis
- coreopsis
- basalis
- coreopsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 72
- 239000003472 antidiabetic agent Substances 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 4
- 235000010554 Coreopsis tinctoria var. tinctoria Nutrition 0.000 title abstract 6
- 229940125708 antidiabetic agent Drugs 0.000 title 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 38
- QMVODIKHHIRSGI-RWGOFXMDSA-N (e)-3-(3,4-dihydroxyphenyl)-1-[2-hydroxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 QMVODIKHHIRSGI-RWGOFXMDSA-N 0.000 claims abstract description 16
- QMVODIKHHIRSGI-UHFFFAOYSA-N 4'-beta-D-glucopyranosyloxy-3,4,2'-trihydroxy-trans-chalcone Natural products OC1C(O)C(O)C(CO)OC1OC(C=C1O)=CC=C1C(=O)C=CC1=CC=C(O)C(O)=C1 QMVODIKHHIRSGI-UHFFFAOYSA-N 0.000 claims abstract description 16
- BVGZTRWADYNRBE-UHFFFAOYSA-N Coreopsin Natural products OCC1OC(Oc2ccc(C=CC(=O)c3ccc(O)cc3O)cc2O)C(O)C(O)C1O BVGZTRWADYNRBE-UHFFFAOYSA-N 0.000 claims abstract description 16
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims abstract description 11
- XGEYXJDOVMEJNG-HTFDPZBKSA-N Marein Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 XGEYXJDOVMEJNG-HTFDPZBKSA-N 0.000 claims abstract description 11
- XGEYXJDOVMEJNG-CMWLGVBASA-N Marein Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1O)O)=CC=C1C(=O)C=CC1=CC=C(O)C(O)=C1 XGEYXJDOVMEJNG-CMWLGVBASA-N 0.000 claims abstract description 11
- 235000005513 chalcones Nutrition 0.000 claims abstract description 11
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000010438 heat treatment Methods 0.000 claims abstract description 5
- 240000003707 Coreopsis basalis Species 0.000 claims description 45
- 239000012530 fluid Substances 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 230000003178 anti-diabetic effect Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 239000008103 glucose Substances 0.000 abstract description 7
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 abstract description 4
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 3
- 230000000452 restraining effect Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 241000723353 Chrysanthemum Species 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 0 *=C(C=Cc(cc1O)ccc1O)C(CCC(C1O)O)=C1O Chemical compound *=C(C=Cc(cc1O)ccc1O)C(CCC(C1O)O)=C1O 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000131317 Capitulum Species 0.000 description 1
- 241000288027 Chrysolophus pictus Species 0.000 description 1
- 241000723366 Coreopsis Species 0.000 description 1
- 235000005912 Coreopsis cardaminifolia Nutrition 0.000 description 1
- 241000132544 Coreopsis tinctoria Species 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an extract containing marein, golden wave chalcone and coreopsin obtained by extracting golden wave in backflow mode which is heated through carbinol, golden wave or an extract containing marein and golden wave chalcone and free of coreopsin obtained by extracting and heating by water. The golden wave extract is externally provided with DPPIV restraining activity, is capable of improving sugar tolerance of 2 type diabetes mellitus mice, is capable of reducing fasting blood-glucose, and is better in medicine effect compared with extracts without coreopsin.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to from Coreopsis basalis to extract and have diabetes active drug composition.
Background technology
Coreopsis basalis (Coreopsis tinctoria Nuff.) has another name called the snow chrysanthemum, is the dry capitulum of Compositae (compositae) golden pheasant Chrysanthemum (Coreopsis), single-lobe, polyphyll or half polyphyll, and ligulate flower is yellow or golden yellow, 6～JIUYUE of florescence.The Flos Caryophylli Coreopsis basalis belongs to the north temperate zone plant; Originate in the North America, Florida state and Mexico state, China introduced a fine variety son as ornamental plant in 1936 and cultivates to Mount Lushan, the Southern Mountain and other places; Various places are except that confession is viewed and admired at present; Also use all herbal medicine, and the food coloring that from spend, extracts, the effect of heat-clearing and toxic substances removing and blood pressure lowering had.The Xinjiang Coreopsis basalis is distributed widely in the mountain area, the Kunlun of about 3000 meters of Hotan Prefecture's height above sea levels, and more rich wild resource is arranged, and often its dry flower is used for making tea among the people.
Summary of the invention
The objective of the invention is to extract and have diabetes active drug composition from Coreopsis basalis.
The present invention realizes that the technical scheme that above-mentioned purpose adopts is following:
The Coreopsis basalis extract; Its method for distilling is: the Coreopsis basalis head inflorescence is pulverized, and is heating and refluxing extraction in 60～80% the methanol in mass concentration, and temperature is 50～70 ℃; The methanol that concentrating under reduced pressure reclaims in the extracting solution obtains fluid extract; Fluid extract is used ethyl acetate extraction, and extract obtains the Coreopsis basalis extract through concentrated, drying, contains marein, Coreopsis basalis chalcone and coreopsin in the extract.
Further, Coreopsis basalis head inflorescence powder and mass concentration are that the mass ratio of 60～80% methanol is 1 during reflux, extract: (25～30).
Another kind of Coreopsis basalis extract, its method for distilling is: the Coreopsis basalis head inflorescence is pulverized heating and refluxing extraction in water; Temperature is 60-80 ℃, and concentrating under reduced pressure obtains fluid extract, polyamide column on the fluid extract; Using mass concentration is that 30～95% ethanol carries out gradient elution; Eluent obtains the Coreopsis basalis extract through concentrated, drying, contains marein and Coreopsis basalis chalcone in the extract, does not contain coreopsin.
Further, the mass ratio of Coreopsis basalis head inflorescence powder and water is 1 during reflux, extract: (25～30).
Further, the application of above-mentioned Coreopsis basalis extract in the preparation antidiabetic medicine.
Said marein has following structural formula:
Said Coreopsis basalis chalcone has following structural formula:
Said coreopsin has following structural formula:
Beneficial effect: the extraction of active drug composition adopts alcohol extraction or water to put forward two kinds of methods usually in the plant; The present invention's discovery all can extract from Coreopsis basalis with methanol or water and contain marein and Coreopsis basalis chalcone; Compare with water extract, when using methanol extraction, extract also contains coreopsin; Prepared ethanol extract or water extract have carried out effect experiment to the type 2 diabetes mellitus mice; The result shows that the Coreopsis basalis extract can improve the carbohydrate tolerance of type 2 diabetes mellitus mice, and the effect that reduces fasting glucose is arranged, and it is better than the drug effect that does not contain coreopsin to contain coreopsin in the extract; The external effect with inhibition DPPIV of Coreopsis basalis extract, the mechanism of its blood sugar lowering possibly act on relevant therewith.
The specific embodiment
Below in conjunction with embodiment the present invention is described further.
The chemical constituent of extract adopts LC-MS appearance (LC/MS) to carry out qualitative analysis.
Embodiment 1
Xinjiang Coreopsis basalis head inflorescence was through pulverizing the 20-50 mesh sieve, used mass concentration to be methanol, the 50-70 ℃ reflux, extract, of 60-80% 2 times, each 2h, and the feed liquid mass ratio is 1:25, merges 2 times extracting solution, concentrating under reduced pressure recovery solvent gets fluid extract.Methanol is carried logistics extractum with equal-volume ethyl acetate extraction 1-3 time, and combining extraction liquid after Rotary Evaporators concentrates, obtains ethyl acetate extraction extractum; Thermostatic drying chamber is dry, obtains the crocus powder.
Embodiment 2
Xinjiang Coreopsis basalis head inflorescence adds water through pulverizing the 20-50 mesh sieve, 60-80 ℃ of reflux, extract, 2 times, and each 2h, the feed liquid mass ratio is 1:25, merges 2 times extracting solution, concentrating under reduced pressure gets fluid extract.Polyamide column on the water extract fluid extract uses mass concentration to carry out gradient elution as the ethanol of 30%-95%, collects eluent, concentrates through Rotary Evaporators, and thermostatic drying chamber is dry, obtains brown ceramic powder.
The evaluation of embodiment 3 extract components
Precision takes by weighing embodiment 1 and each 10mg of extract that embodiment 2 makes, and places the 10ml volumetric flask respectively, adds that methanol is ultrasonic to make its dissolving, is settled to scale, and filter membrane (0.22 μ m) filters twice, and is subsequent use.Precision takes by weighing marein reference substance, coreopsin reference substance and Coreopsis basalis chalcone reference substance 4.69mg, 4.97mg and 4.82mg respectively; With the chromatograph dissolve with methanol and be settled in the 10mL volumetric flask, obtain the standard solution that concentration is respectively 0.469mg/mL, 0.497mg/mL and 0.482 mg/mL.LC/MS chromatographic condition: chromatographic column: HyPersil BDS C
18(4.6mm * 250nm, 5 μ m); Chromatographic peak acquisition range: 190nm～400nm; Mobile phase: methanol (A)-0.5% (quality) formic acid solution (B), the gradient elution program sees the following form; Flow velocity: 0.8mlmin
-1Column temperature: 25 ℃; Sample size: 10 μ l; Detect wavelength: 290nm; MS condition: the full ion scan of 100-800 karyoplasmic ratio.
LC/MS result shows, contains marein, Coreopsis basalis chalcone and three kinds of working substances of coreopsin during embodiment 1 is extract obtained, contains marein and Coreopsis basalis chalcone, no coreopsin during embodiment 2 is extract obtained.
Embodiment 4 pharmacodynamic experiments
One, the foundation of type 2 diabetes mellitus mouse model
140 of cleaning level male mouse of kunming; Body weight 18-22g; Wherein feed as normal control group normal feedstuff for 10; In addition 130 as model group with one week of high glucose and high fat forage feed, fasting is after 8 hours, lumbar injection streptozotocin (STZ solution) 180mg/kg (the normal control group gives the aseptic citric acid-sodium citrate buffer of equal volume).After 72 hours, 2h carbohydrate tolerance test (OGTT) is carried out in fasting 12 hours, blood glucose >=11.1mmol/L person's modeling success.
Two, become mould mice group and administration
Become the grouping of mould mice
Get into 88 of mould mices; Be divided into 8 groups at random according to body weight: model group, metformin positive control drug group, the heavy dose of group of embodiment 1 extract obtained branch, middle dose groups, small dose group; The heavy dose of group of embodiment 2 extract obtained branches, middle dose groups, small dose group; Add totally 9 groups of aforementioned normal control groups, every group guarantees more than 10.
Become the administration of mould mice
Each is organized in every morning and irritates stomach, and 1 time/day, normal group and model group are irritated normal saline, successive administration 30 days.Mice tail point is weekly got a blood survey fasting glucose (FBG) and oral glucose tolerance experiment (OGTT).
Three, experimental result
Before the administration, model group and each administration group FBG and OGTT there was no significant difference.After 2 weeks of administration, begin, the FBG of metformin group and OGTT continue to reduce obviously, and embodiment 1 heavy dose of group FBG and OGTT also reduce; After 4 weeks of administration, embodiment 1 heavy dose of group FBG and OGTT and model group relatively have notable difference (
P<0.01), and among the embodiment 1 dose groups FBG and OGTT and model group more also have significant difference (
P<0.05), embodiment 2 heavy dose of with middle dose groups FBG and OGTT and model group more all have significant difference (
P<0.05), embodiment 1 small dose group, embodiment 2 small dose group FBG and OGTT and model group be the indifference opposite sex relatively.Concrete outcome is following:
The external influence of embodiment 5 Coreopsis basalis extracts to DPP IV (DPP IV)
With the dried powder of two kinds of Coreopsis basalis extracts of embodiment 1 and embodiment 2 gained, be mixed with the solution of variable concentrations gradient.Experiment is divided into 4 groups, establishes 3 multiple holes, is respectively blank group (buffer+substrate) for every group; Negative control group (enzyme+buffer+substrate); Experiment blank group (extract+buffer+substrate) (extract is a colored substance, self color interference can occur when detecting at the 405nm place, and the blank that therefore every kind of each concentration of extract is set when detecting is avoided the false positive phenomenon as far as possible); Experimental group (extract+enzyme+buffer+substrate), the suppression ratio of observing variable concentrations changes.At first with each extract, DPPIV, substrate and buffer water-bath 30min under 37 ℃ of temperature, the order according to extract, enzyme, buffer, substrate adds in 96 orifice plates addition such as table 1 successively then; Hatch 60min for 37 ℃, under the 405nm wavelength, record the OD value.
Experimental result is following:
More than experiment shows that the Coreopsis basalis extract can improve the carbohydrate tolerance of type 2 diabetes mellitus mice and the effect that reduces fasting glucose is arranged; Wherein, The effect that embodiment 1 makes extract is better than the effect that embodiment 2 makes extract; Explain that to contain coreopsin in the extract better than the drug effect that does not contain coreopsin, two kinds of Coreopsis basalis extracts are external to have the effects that suppress DPPIV, and the mechanism of its blood sugar lowering possibly act on relevant therewith.
Claims (5)
1. the Coreopsis basalis extract is characterized in that, this extract is to obtain by following method for distilling: the Coreopsis basalis head inflorescence is pulverized; In mass concentration is heating and refluxing extraction in 60～80% the methanol; Temperature is 50～70 ℃, and the methanol that concentrating under reduced pressure reclaims in the extracting solution obtains fluid extract, and fluid extract is used ethyl acetate extraction; Extract obtains the Coreopsis basalis extract through concentrated, drying, contains marein, Coreopsis basalis chalcone and coreopsin in the extract.
2. Coreopsis basalis extract according to claim 1 is characterized in that: Coreopsis basalis head inflorescence powder and mass concentration are that the mass ratio of 60～80% methanol is 1 during reflux, extract: (25～30).
3. another kind of Coreopsis basalis extract is characterized in that, this extract is to obtain by following method for distilling: the Coreopsis basalis head inflorescence is pulverized; Heating and refluxing extraction in water, temperature is 60～80 ℃, concentrating under reduced pressure obtains fluid extract; Polyamide column on the fluid extract, using mass concentration is that 30%～95% ethanol carries out gradient elution, eluent through concentrate, drying obtains the Coreopsis basalis extract; Contain marein and Coreopsis basalis chalcone in the extract, do not contain coreopsin.
4. Coreopsis basalis extract according to claim 3 is characterized in that: the mass ratio of Coreopsis basalis head inflorescence powder and water is 1 during reflux, extract: (25～30).
5. any described Coreopsis basalis extract of claim 1 to 4 is characterized in that: the application of said Coreopsis basalis extract in the preparation antidiabetic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210141831.1A CN102641317B (en) | 2012-05-09 | 2012-05-09 | Golden wave extract and application thereof in preparation of antidiabetic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210141831.1A CN102641317B (en) | 2012-05-09 | 2012-05-09 | Golden wave extract and application thereof in preparation of antidiabetic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102641317A true CN102641317A (en) | 2012-08-22 |
| CN102641317B CN102641317B (en) | 2014-12-03 |
Family
ID=46654562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210141831.1A Active CN102641317B (en) | 2012-05-09 | 2012-05-09 | Golden wave extract and application thereof in preparation of antidiabetic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102641317B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222996A (en) * | 2013-05-15 | 2013-07-31 | 顾海 | Coreopsis tinctoria refined extract and medical application thereof |
| CN103989691A (en) * | 2014-02-27 | 2014-08-20 | 中国医学科学院药用植物研究所 | Application of marein in preventing and treating cognition impairments induced by pyruvic aldehyde pyruvaldehyde |
| CN104098624A (en) * | 2014-07-29 | 2014-10-15 | 新疆农业大学 | Preparation and application of composite chalcone glycoside compound of Coreopsis tinctoria Nutt |
| CN104173400A (en) * | 2014-07-02 | 2014-12-03 | 苏州大学 | Coreopsis tinctoria nutt extract and application thereof |
| CN107648294A (en) * | 2017-11-13 | 2018-02-02 | 新疆维吾尔自治区药物研究所 | The purposes in treating vascular dementia medicine is being prepared containing the double-colored golden wave active component of marein |
| CN108929209A (en) * | 2018-08-01 | 2018-12-04 | 新疆医科大学 | The extracting method of okanin in snow chrysanthemum |
| CN109010406A (en) * | 2018-08-20 | 2018-12-18 | 上海拉德钫斯生物科技有限公司 | A kind of preparation method for the coreopsis tinctoria extract improving diabetic nephropathy |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048786A (en) * | 2010-12-09 | 2011-05-11 | 新疆维吾尔自治区药物研究所 | Preparation and application of coreopsis extract |
| CN102058649A (en) * | 2009-11-18 | 2011-05-18 | 新疆维吾尔自治区药物研究所 | Application of extract of Coreopsis tinctoria Nuff. to preparation of medicaments or health foods for treating hypertension and hyperlipidemia |
-
2012
- 2012-05-09 CN CN201210141831.1A patent/CN102641317B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058649A (en) * | 2009-11-18 | 2011-05-18 | 新疆维吾尔自治区药物研究所 | Application of extract of Coreopsis tinctoria Nuff. to preparation of medicaments or health foods for treating hypertension and hyperlipidemia |
| CN102048786A (en) * | 2010-12-09 | 2011-05-11 | 新疆维吾尔自治区药物研究所 | Preparation and application of coreopsis extract |
Non-Patent Citations (6)
| Title |
|---|
| 《中国实验方剂学杂志》 20110430 张燕等 新疆昆仑雪菊5种提取物对alpha-葡萄糖苷酶活性的影响 166-169 1-5 第17卷, 第07期 * |
| 《现代生物医学进展》 20110331 张淑鹏等 昆仑雪菊提取物对alpha-葡萄糖苷酶的抑制作用 1055-1058 1-5 第11卷, 第06期 * |
| TERESA DIAS ET AL.: "The flavonoid-rich fraction of Coreopsis tinctoria promotes glucose tolerance regain through pancreatic function recovery in streptozotocin-induced glucose-intolerant rats", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 张淑鹏等: "昆仑雪菊提取物对α-葡萄糖苷酶的抑制作用", 《现代生物医学进展》 * |
| 张燕等: "新疆昆仑雪菊5种提取物对α-葡萄糖苷酶活性的影响", 《中国实验方剂学杂志》 * |
| 梁淑红等: "金鸡菊提取物降血脂作用的动物实验研究", 《农垦医学》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222996A (en) * | 2013-05-15 | 2013-07-31 | 顾海 | Coreopsis tinctoria refined extract and medical application thereof |
| CN103989691A (en) * | 2014-02-27 | 2014-08-20 | 中国医学科学院药用植物研究所 | Application of marein in preventing and treating cognition impairments induced by pyruvic aldehyde pyruvaldehyde |
| CN104173400A (en) * | 2014-07-02 | 2014-12-03 | 苏州大学 | Coreopsis tinctoria nutt extract and application thereof |
| CN104173400B (en) * | 2014-07-02 | 2018-01-02 | 苏州大学 | A kind of coreopsis tinctoria extract and its application |
| CN104098624A (en) * | 2014-07-29 | 2014-10-15 | 新疆农业大学 | Preparation and application of composite chalcone glycoside compound of Coreopsis tinctoria Nutt |
| CN107648294A (en) * | 2017-11-13 | 2018-02-02 | 新疆维吾尔自治区药物研究所 | The purposes in treating vascular dementia medicine is being prepared containing the double-colored golden wave active component of marein |
| CN108929209A (en) * | 2018-08-01 | 2018-12-04 | 新疆医科大学 | The extracting method of okanin in snow chrysanthemum |
| CN108929209B (en) * | 2018-08-01 | 2021-11-09 | 新疆医科大学 | Method for extracting ocainin from coreopsis tinctoria |
| CN109010406A (en) * | 2018-08-20 | 2018-12-18 | 上海拉德钫斯生物科技有限公司 | A kind of preparation method for the coreopsis tinctoria extract improving diabetic nephropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102641317B (en) | 2014-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102641317B (en) | Golden wave extract and application thereof in preparation of antidiabetic agent | |
| CN101411745B (en) | Antibiotic tanshinone extract, preparation method thereof, use and products produced thereby | |
| CN101863871B (en) | Total glycosides of Rhodiola rosea, medical application and preparation method thereof | |
| CN101385748A (en) | Maniod ebish flower extract, extraction and analysis method and extract preparation and use thereof | |
| CN101244129A (en) | Lhasa rhubarb extract, preparation method, and application in preparing preparation for treating cardiovascular and cerebrovascular diseases | |
| CN103599148A (en) | Agriophyllum squarrosum total flavonoid extract, and preparation method and application thereof | |
| CN101229335B (en) | Method for Enzymatically Preparing Smilax Smilax Total Saponins Extract | |
| CN103536635A (en) | Preparation method of holothuria nobilis and application thereof in treatment of diabetes mellitus | |
| CN102266369A (en) | Application of calliopsis extract to liver protection and antioxidation | |
| CN103230517A (en) | Adenophora radix ophiopogonis soup formula granules as well as preparation method and detection method thereof | |
| CN102178821A (en) | Soft capsules for reducing blood sugar and preparation method thereof | |
| CN103040945B (en) | Preparation and detection method of gangsong general flavones | |
| CN102526138B (en) | Composition of active components from fresh purslane for decreasing blood sugar and preparation method | |
| CN102356837B (en) | Combined food for reducing blood sugar | |
| CN102357131A (en) | Method for preparing astragalus polysaccharide glucose-lowering capsule | |
| CN1861104B (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN103239435B (en) | Preparation method of gynura divaricata total caffeoylquinic acid and application in antihyperglycemic agent or health-care product | |
| CN106539825B (en) | Kelp root product for reducing blood sugar and preparation method and application thereof | |
| CN106279315B (en) | One kind preparing Quercetin -3-O-2 from ginkgo biloba p.e ", the method for 6 "-two rhamnopyranosyl glucosides | |
| CN103263467A (en) | Potent medicament of brain-and-heart, preparation method and content determination | |
| CN101450105B (en) | Herba swertiae preparation and quality control method thereof | |
| CN103705723B (en) | Pharmaceutical composition of a kind of kidney tonifying hypoglycemic and preparation method thereof and application | |
| CN101176755B (en) | Application of meletin-7-0-glycoside in mass control of cudrania tricuspidata or preparations thereof | |
| CN100563669C (en) | The preparation method of Herba Blumeae Balsamiferae total flavones extract and Herba Blumeae Balsamiferae total flavones extract | |
| CN100488553C (en) | Extractive of bullbrier genus plants, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160113 Address after: 830011 the Xinjiang Uygur Autonomous Region high tech Zone of Urumqi city (urban) Beijing Road No. 556 diamond Baixin building 4 court A shop floor room 15 Patentee after: Xinjiang agricultural biological Polytron Technologies Inc Address before: 830000, room 4, building 1, 458, science building, No. 416-427, Northwest Road, the Xinjiang Uygur Autonomous Region, Urumqi Patentee before: Urumqi Sangaohe Pharmaceutical Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210809 Address after: 830011 shop 14, floor 4, building a, Baixin Diamond Garden, No. 556, Beijing South Road, high tech Zone (new urban area), Urumqi, Xinjiang Uygur Autonomous Region Patentee after: Xinjiang Xueju Bio-technology Co.,Ltd. Address before: 830011 room 15, shop 4 / F, building a, Baixin Diamond Garden, No. 556, Beijing South Road, high tech Zone (new urban area), Urumqi, Xinjiang Patentee before: XINJIANG NONGDING BIOTECHNOLOGY Co.,Ltd. |